Cognitive Muscular Therapy for Patients With Long-COVID and Breathing Pattern Disorder

Launched by UNIVERSITY OF SALFORD · Jul 15, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment called Cognitive Muscular Therapy (CMT) for patients who are experiencing long-COVID symptoms, particularly those who struggle with breathlessness and issues related to their body's automatic functions, like breathing and heart rate. The goal is to see if CMT can help reduce difficulties with breathing and improve overall health for those affected by long-COVID.

To participate in this study, individuals need to be over 18 years old and should be experiencing moderate to severe breathlessness. Participants must also be able to understand English well enough to follow instructions and stand without help for at least 20 minutes. However, people with certain conditions, such as dementia, serious heart issues, or those currently receiving other treatments for breathing problems, will not be eligible. If you join the trial, you can expect to learn more about your breathing patterns and potentially benefit from a new approach to managing your symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Above 18 years old
• • Experience moderate/severe breathlessness, quantified using the Modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) scale.
• • Speak and understand English sufficiently to read the information sheet and sign the consent form
• • Ability to stand without any assistive device for at least 20 minutes (to ensure sufficient capacity to complete the intervention)
• Exclusion Criteria:
• • Dementia or other major cognitive impairment
• • BMI \>32 (as increased subcutaneous fat prevents use of breathing measurement system)
• • Current smoker or smoked regularly within last 6 months
• • Any cardiorespiratory disease that requires medical intervention (except asthma management)
• • Currently receiving physiotherapy-based treatment for LC or breathing pattern disorder
• • Significant respiratory co-morbidity (e.g. COPD, uncontrolled Asthma)